Published in Br J Cancer on February 01, 2000
Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA (2006) 4.34
Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. J Mol Diagn (2008) 2.30
Conventional and tissue microarray immunohistochemical expression analysis of mismatch repair in hereditary colorectal tumors. Am J Pathol (2003) 1.67
Use of microsatellite instability and immunohistochemistry testing for the identification of individuals at risk for Lynch syndrome. Fam Cancer (2005) 1.47
The utility of immunohistochemical detection of DNA mismatch repair gene proteins. Virchows Arch (2004) 1.09
Accuracy of MSI testing in predicting germline mutations of MSH2 and MLH1: a case study in Bayesian meta-analysis of diagnostic tests without a gold standard. Biostatistics (2005) 1.05
Contrasting molecular pathology of colorectal carcinoma in Egyptian and Western patients. Br J Cancer (2001) 1.03
Clinicopathological and molecular genetic analysis of 4 typical Chinese HNPCC families. World J Gastroenterol (2001) 0.95
Clinical characteristics and diagnosis of patients with hereditary nonpolyposis colorectal cancer. World J Gastroenterol (2003) 0.92
Immunohistochemistry and microsatellite instability analysis in molecular subtyping of colorectal carcinoma based on mismatch repair competency. Int J Clin Exp Med (2015) 0.83
Prevalence of pathological germline mutations of hMLH1 and hMSH2 genes in colorectal cancer. PLoS One (2013) 0.82
Human mismatch repair protein hMutLα is required to repair short slipped-DNAs of trinucleotide repeats. J Biol Chem (2012) 0.82
Is reduced expression of mismatch repair genes MLH1 and MSH2 in patients with sporadic colorectal cancer related to their prognosis? Clin Exp Metastasis (2002) 0.82
Oligonucleotide-directed mutagenesis screen to identify pathogenic Lynch syndrome-associated MSH2 DNA mismatch repair gene variants. Proc Natl Acad Sci U S A (2016) 0.81
Mismatch repair protein expression in colorectal cancer. J Gastrointest Oncol (2013) 0.79
An American founder mutation in MLH1. Int J Cancer (2011) 0.79
Assessing pathogenicity of MLH1 variants by co-expression of human MLH1 and PMS2 genes in yeast. BMC Cancer (2009) 0.78
Clinical and molecular biologic characteristics of early-onset versus late-onset colorectal carcinoma in Filipinos. World J Surg (2004) 0.78
Partial loss of heterozygosity events at the mutated gene in tumors from MLH1/MSH2 large genomic rearrangement carriers. BMC Cancer (2009) 0.77
Q48P mutation in the hMLH1 gene associated with Lynch syndrome in three Hungarian families. Fam Cancer (2012) 0.77
HMLH1 gene mutation in gastric cancer patients and their kindred. World J Gastroenterol (2005) 0.77
Human mutL homolog 1 expression characteristic and prognostic effect on patients with sporadic colorectal cancer. Int J Clin Exp Med (2015) 0.75
Performance of Lynch syndrome predictive models in quantifying the likelihood of germline mutations in patients with abnormal MLH1 immunoexpression. Fam Cancer (2017) 0.75
Lessons from hereditary colorectal cancer. Cell (1996) 25.73
The 1993-94 Généthon human genetic linkage map. Nat Genet (1994) 17.64
The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell (1993) 13.54
Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature (1993) 12.74
Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science (1989) 11.53
Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell (1993) 9.93
The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum (1991) 9.82
Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A (1998) 9.66
Mutation of a mutL homolog in hereditary colon cancer. Science (1994) 9.04
Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res (1997) 8.88
Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med (1998) 8.47
Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature (1994) 8.04
Regulation of intracellular beta-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein. Proc Natl Acad Sci U S A (1995) 7.31
BRCA1 mutations in primary breast and ovarian carcinomas. Science (1994) 6.81
Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature (1994) 6.21
Cancer-susceptibility genes. Gatekeepers and caretakers. Nature (1997) 5.87
A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst (1997) 5.68
Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer. Cancer Res (1995) 5.26
Analysis of mismatch repair genes in hereditary non-polyposis colorectal cancer patients. Nat Med (1996) 4.87
Diagnostic microsatellite instability: definition and correlation with mismatch repair protein expression. Cancer Res (1997) 4.61
Isolation of an hMSH2-p160 heterodimer that restores DNA mismatch repair to tumor cells. Science (1995) 4.48
Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability. Nat Genet (1995) 4.01
Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer (1993) 3.86
Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology (1996) 3.54
Germline mutation of MSH6 as the cause of hereditary nonpolyposis colorectal cancer. Nat Genet (1997) 3.34
Molecular nature of colon tumors in hereditary nonpolyposis colon cancer, familial polyposis, and sporadic colon cancer. Gastroenterology (1996) 3.30
MLH1, PMS1, and MSH2 interactions during the initiation of DNA mismatch repair in yeast. Science (1994) 3.19
Genetic instability occurs in the majority of young patients with colorectal cancer. Nat Med (1995) 3.07
Altered expression of hMSH2 and hMLH1 in tumors with microsatellite instability and genetic alterations in mismatch repair genes. Cancer Res (1996) 2.89
Hereditary nonpolyposis colorectal cancer (Lynch syndrome). An updated review. Cancer (1996) 2.44
Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res (1996) 2.37
p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene (1997) 2.31
Germ-line mutation of the hMSH6/GTBP gene in an atypical hereditary nonpolyposis colorectal cancer kindred. Cancer Res (1997) 2.28
Loss of the wild type MLH1 gene is a feature of hereditary nonpolyposis colorectal cancer. Nat Genet (1994) 2.08
Conditional mutator phenotypes in hMSH2-deficient tumor cell lines. Science (1997) 2.04
Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group. Hum Mol Genet (1998) 1.88
Microsatellite instability and mutation analysis of hMSH2 and hMLH1 in patients with sporadic, familial and hereditary colorectal cancer. Hum Mol Genet (1996) 1.76
Somatic mutations in the BRCA1 gene in sporadic ovarian tumours. Nat Genet (1995) 1.75
Alternative genetic pathways in colorectal carcinogenesis. Proc Natl Acad Sci U S A (1997) 1.68
Excess beta-catenin promotes accumulation of transcriptionally active p53. EMBO J (1999) 1.63
Somatic mutations in the hMSH2 gene in microsatellite unstable colorectal carcinomas. Hum Mol Genet (1995) 1.57
Genetic instability in human ovarian cancer cell lines. Proc Natl Acad Sci U S A (1994) 1.56
Accumulated clonal genetic alterations in familial and sporadic colorectal carcinomas with widespread instability in microsatellite sequences. Am J Pathol (1998) 1.55
HNPCC associated with germline mutation in the TGF-beta type II receptor gene. Nat Genet (1998) 1.45
Microsatellite instability analysis: a multicenter study for reliability and quality control. Cancer Res (1997) 1.43
Binding of mismatched microsatellite DNA sequences by the human MSH2 protein. Science (1994) 1.41
Overview of natural history, pathology, molecular genetics and management of HNPCC (Lynch Syndrome). Int J Cancer (1996) 1.38
Functional analysis of human MLH1 mutations in Saccharomyces cerevisiae. Nat Genet (1998) 1.33
DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene (1996) 1.31
The tumour spectrum in hereditary non-polyposis colorectal cancer: a study of 24 kindreds in the Netherlands. Int J Cancer (1990) 1.24
A naturally occurring hPMS2 mutation can confer a dominant negative mutator phenotype. Mol Cell Biol (1998) 1.11
Mutational analysis of MLH1 and MSH2 in 25 prospectively-acquired RER+ endometrial cancers. Genes Chromosomes Cancer (1997) 1.04
Characterization of MLH1 and MSH2 alternative splicing and its relevance to molecular testing of colorectal cancer susceptibility. Hum Genet (1998) 1.03
Tumour spectrum in hereditary non-polyposis colorectal cancer (HNPCC) and in families with "suspected HNPCC". A population-based study in northern Italy. Colorectal Cancer Study Group. Int J Cancer (1993) 1.03
RNA-based mutation screening in hereditary nonpolyposis colorectal cancer. Am J Hum Genet (1996) 0.96
MLH1 and MSH2 constitutional mutations in colorectal cancer families not meeting the standard criteria for hereditary nonpolyposis colorectal cancer. Int J Cancer (1998) 0.95
Germline HNPCC gene variants have little influence on the risk for sporadic colorectal cancer. J Med Genet (1997) 0.94
Alternative splicing of hMSH2 in normal human tissues. Hum Genet (1997) 0.90
Bcl-2 expression in normal endometrium during the menstrual cycle. Am J Pathol (1994) 0.88
A truncated hMSH2 transcript occurs as a common variant in the population: implications for genetic diagnosis. Cancer Res (1996) 0.88
K-ras and p53 mutations in hereditary non-polyposis colorectal cancers. Int J Cancer (1997) 0.86
A simple model for carcinogenesis of colorectal cancers with microsatellite instability. Adv Cancer Res (2000) 0.84
Germline hMSH2 and hMLH1 gene mutations in incomplete HNPCC families. Int J Cancer (1997) 0.83
Tumor variation in three extended Lynch syndrome II kindreds. Am J Gastroenterol (1988) 0.83
Familial risk and colon cancer. Int J Cancer (1996) 0.81
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet (2000) 12.56
Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer (2007) 5.38
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol (2001) 5.25
Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med (1999) 4.81
Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol (2002) 3.91
Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol (1998) 3.79
Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet (2010) 3.21
Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol (1997) 3.08
First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol (2002) 2.87
Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc Natl Acad Sci U S A (1995) 2.56
Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. J Clin Oncol (2000) 2.48
Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer (1999) 2.40
During liver regeneration following right portal embolization the growth rate of liver metastases is more rapid than that of the liver parenchyma. Br J Surg (1999) 2.37
P53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br J Cancer (2000) 2.35
Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol (2004) 2.24
Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients. Ann Oncol (2006) 2.18
Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol (2002) 2.15
Postoperative pulmonary complications. Epidural analgesia using bupivacaine and opioids versus parenteral opioids. Anesthesiology (1993) 2.14
Surgical management of primary anorectal melanoma. Br J Surg (2004) 2.14
Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice. Cancer Res (1985) 2.06
Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol (1998) 2.05
Detection of minority point mutations by modified PCR technique: a new approach for a sensitive diagnosis of tumor-progression markers. Nucleic Acids Res (1989) 2.04
Radiofrequency ablation of 100 hepatic metastases with a mean follow-up of more than 1 year. AJR Am J Roentgenol (2000) 1.95
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer (2004) 1.94
Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol (2009) 1.93
Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst (1996) 1.93
Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer (2001) 1.92
ASTRO (American Society for Therapeutic Radiology and Oncology) plenary: Effect of chemotherapy on locally advanced non-small cell lung carcinoma: a randomized study of 353 patients. GETCB (Groupe d'Etude et Traitement des Cancers Bronchiques), FNCLCC (Féderation Nationale des Centres de Lutte contre le Cancer) and the CEBI trialists. Int J Radiat Oncol Biol Phys (1991) 1.91
Intermittent vascular exclusion of the liver (without vena cava clamping) during major hepatectomy. Br J Surg (1995) 1.88
Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group. Hum Mol Genet (1998) 1.88
A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol (1990) 1.86
Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC. J Hepatol (1998) 1.80
Resection of liver metastases from a noncolorectal primary: indications and results based on 147 monocentric patients. J Am Coll Surg (1998) 1.79
Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J Med Genet (2005) 1.78
Thermal hyperalgesia as a marker of oxaliplatin neurotoxicity: a prospective quantified sensory assessment study. Pain (2009) 1.77
Cholesterol, a cell size-dependent signal that regulates glucose metabolism and gene expression in adipocytes. J Biol Chem (2001) 1.74
Percutaneous radiofrequency thermoablation as an alternative to surgery for treatment of liver tumour recurrence after hepatectomy. Br J Surg (2002) 1.74
Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2012) 1.72
Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N Engl J Med (1993) 1.69
Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2012) 1.67
Determination of total and segmental colonic transit time in constipated patients. Results in 91 patients with a new simplified method. Dig Dis Sci (1989) 1.67
Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference: Perspectives in Colorectal Cancer, Dublin, 2001). Eur J Cancer (2002) 1.66
Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. Cancer (1985) 1.66
Frequency, technical aspects, results, and indications of major hepatectomy after prolonged intra-arterial hepatic chemotherapy for initially unresectable hepatic tumors. J Am Coll Surg (1995) 1.64
A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma. Ann Oncol (2002) 1.61
Predictive value of in vitro radiosensitivity parameters in head and neck cancers and cervical carcinomas: preliminary correlations with local control and overall survival. Int J Radiat Oncol Biol Phys (1993) 1.60
Long-term outcome of patients with gastrointestinal bleeding of obscure origin explored by push enteroscopy. Endoscopy (2002) 1.60
N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique. J Clin Oncol (1997) 1.59
Chemotherapy as an adjunct to radiotherapy in locally advanced nasopharyngeal carcinoma. Cochrane Database Syst Rev (2006) 1.58
A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial. Eur J Cancer (2005) 1.58
Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer. Ann Oncol (2006) 1.55
Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol (2002) 1.55
Nonsteroidal anti-inflammatory drug-induced colonic strictures: two cases and literature review. Am J Gastroenterol (1995) 1.53
The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma; a judicious option? Eur J Cancer (2004) 1.52
Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients. Ann Oncol (2004) 1.51
Frequent alteration of DNA damage signalling and repair pathways in human colorectal cancers with microsatellite instability. Oncogene (2007) 1.50
Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol (2004) 1.49
Electromyography of the colon in situ. An experimental study in man and in the rabbit. Gastroenterology (1969) 1.48
Pancreatic tumors: comparison of dual-phase helical CT and endoscopic sonography. AJR Am J Roentgenol (1998) 1.48
Preoperative portal vein embolization for extension of hepatectomy indications. Hepatology (1996) 1.46
Treatment strategy for patients with colorectal cancer and synchronous irresectable liver metastases. Br J Surg (2005) 1.46
[Percutaneous radiofrequency ablation of hepatic metastases. Preliminary experience]. Gastroenterol Clin Biol (1999) 1.45
Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin. Ann Oncol (1998) 1.45
Chromosome 1 in human colorectal tumors. Cytogenetic research on structural changes and their significance. Hum Genet (1992) 1.44
Lobular and ductal carcinomas of the breast have distinct genomic and expression profiles. Oncogene (2008) 1.44
The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006. Ann Oncol (2007) 1.44
Results of 136 curative hepatectomies with a safety margin of less than 10 mm for colorectal metastases. J Surg Oncol (1998) 1.43
Prognosis of advanced hepatocellular carcinoma: comparison of three staging systems in two French clinical trials. Ann Oncol (2008) 1.43
Extrahepatic disease does not contraindicate hepatectomy for colorectal liver metastases. Br J Surg (2003) 1.42
[Measurement of colonic transit time: description and validation of a new method]. Gastroenterol Clin Biol (1986) 1.40
[Is sentinel lymph node mapping relevant for colon cancer?: a feasibility study]. Ann Chir (2003) 1.39
[What are the real indications for hepatectomies in metastases of colorectal origin?]. Gastroenterol Clin Biol (1998) 1.39
Intravenous erythromycin and delayed gastric emptying. Gastrointest Endosc (1993) 1.39
Postoperative hypoxaemia: continuous extradural infusion of bupivacaine and morphine vs patient-controlled analgesia with intravenous morphine. Br J Anaesth (1998) 1.39
Mutations at BRCA1: the medullary breast carcinoma revisited. Cancer Res (1998) 1.39
Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801). Ann Oncol (2005) 1.39
[Perianesthetic management of carcinoid syndrome: contribution of the bispectral EEG index]. Ann Fr Anesth Reanim (2000) 1.38
Simultaneous high-dose external irradiation and daily cisplatin in unresectable, non-metastatic adenocarcinoma of the pancreas: a phase I-II study. Radiother Oncol (1997) 1.38
Usefulness of intraoperative radiofrequency thermoablation of liver tumours associated or not with hepatectomy. Eur J Surg Oncol (2000) 1.36
Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. J Clin Oncol (1998) 1.34